LJPC earnings

La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2022 and highlighted corporate progress. Corporate Progress Net Product Sales: For the three months ended March 31, 2022, La Jolla's net product sales were $10.4 million, up 21% from the same period in 2021. GIAPREZA U.S. Net Product Sales: For the three months ended March 31, 2022, GIAPREZA U.S. net product sales were $7.7 million, up 13% from the same period in 2021. XERAVA U.S. Net Product Sales: For the three months ended

La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted corporate progress. Corporate Progress Record Fourth Quarter and Full Year Net Product Sales: La Jolla had record net product sales for the three and twelve months ended December 31, 2021. For the three and twelve months ended December 31, 2021, La Jolla's net product sales were $12.1 million and $43.5 million, respectively, compared to $11.0 million and $33.4 million, respectively, for the same

La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2021 and highlighted corporate progress. Corporate Progress Increased Net Product Sales: For the three and nine months ended September 30, 2021, La Jolla's net product sales were $11.8 million and $31.5 million, respectively, compared to $9.1 million and $22.5 million, respectively, for the same periods in 2020. La Jolla acquired Tetraphase, which commercialized XERAVA, on July 28, 2020. Net product sales for the thre

La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months ended June 30, 2021 and highlighted corporate progress. Corporate Progress Positive Net Cash Provided by Operating Activities: La Jolla's net cash provided by (used for) operating activities for the three and six months ended June 30, 2021 was $7.1 million and $24.3 million, respectively, compared to $(8.4) million and $(20.6) million, respectively, for the same periods in 2020. La Jolla's net cash provided by (used for) operating activi

La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021 and highlighted corporate progress. Corporate Progress Operating Cash Flow Improved: La Jolla's net cash provided by (used for) operating activities for the three months ended March 31, 2021 was $17.2 million, compared to $(12.2) million for the same period in 2020. La Jolla's net cash provided by (used for) operating activities excluding net receipts in connection with license agreements and payments related

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted corporate progress. Corporate Progress Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe: In January 2021, La Jolla Pharmaceutical Company announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) entered into an exclusive licensing agreement with PAION AG and its who